Surgery Partners (SGRY) Aperçu de l'action
Surgery Partners, Inc. et ses filiales possèdent et exploitent un réseau d'établissements chirurgicaux et de services auxiliaires aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 3/6 |
| Performances passées | 0/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
SGRY Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Surgery Partners, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$14.27 |
| Plus haut sur 52 semaines | US$24.18 |
| Plus bas sur 52 semaines | US$11.41 |
| Bêta | 1.99 |
| Variation sur 1 mois | 16.39% |
| Variation sur 3 mois | -3.97% |
| Variation sur 1 an | -38.17% |
| Variation sur 3 ans | -59.47% |
| Variation sur 5 ans | -72.35% |
| Évolution depuis l'introduction en bourse | -22.57% |
Nouvelles et mises à jour récentes
SGRY: Margin Pressures Will Ease As M&A Optionality Reshapes 2026 Outlook
Analysts have reduced the average price target for Surgery Partners by roughly $8 to $10 per share to a range of about $14 to $24, citing Q4 EBITDA shortfalls, margin pressures from payer and insurance mix shifts, anesthesia related costs, and softer 2026 guidance that excludes potential M&A. Analyst Commentary Recent research shows that while price targets have moved lower across the Street, several bullish analysts still see upside potential for Surgery Partners relative to current trading levels.
SGRY: Margin Repair And Payer Mix Management Will Support A Constructive 2026 Reset
The analyst price target for Surgery Partners has been reduced from about $25.45 to about $18.80. Analysts cite weaker Q4 EBITDA, margin pressure from a tougher payer and insurance mix, anesthesia-related cost pressures, and more cautious 2026 guidance as key drivers of their updated views.SGRY: Margin Reset And M&A Optionality Will Counter Anesthesia And Payer Mix Pressures
Narrative Update on Surgery Partners The analyst price target for Surgery Partners has moved lower by several dollars into a $14 to $24 range, as analysts factor in recent Q4 EBITDA shortfalls, weaker margins, anesthesia and payer mix headwinds, and management's 2026 guidance that sits below prior consensus and assumes limited M&A. Analyst Commentary Recent Street commentary on Surgery Partners centers on Q4 earnings that came in below expectations, margin pressure tied to anesthesia costs, and a less favorable payer mix.Recent updates
SGRY: Margin Pressures Will Ease As M&A Optionality Reshapes 2026 Outlook
Analysts have reduced the average price target for Surgery Partners by roughly $8 to $10 per share to a range of about $14 to $24, citing Q4 EBITDA shortfalls, margin pressures from payer and insurance mix shifts, anesthesia related costs, and softer 2026 guidance that excludes potential M&A. Analyst Commentary Recent research shows that while price targets have moved lower across the Street, several bullish analysts still see upside potential for Surgery Partners relative to current trading levels.SGRY: Margin Repair And Payer Mix Management Will Support A Constructive 2026 Reset
The analyst price target for Surgery Partners has been reduced from about $25.45 to about $18.80. Analysts cite weaker Q4 EBITDA, margin pressure from a tougher payer and insurance mix, anesthesia-related cost pressures, and more cautious 2026 guidance as key drivers of their updated views.SGRY: Margin Reset And M&A Optionality Will Counter Anesthesia And Payer Mix Pressures
Narrative Update on Surgery Partners The analyst price target for Surgery Partners has moved lower by several dollars into a $14 to $24 range, as analysts factor in recent Q4 EBITDA shortfalls, weaker margins, anesthesia and payer mix headwinds, and management's 2026 guidance that sits below prior consensus and assumes limited M&A. Analyst Commentary Recent Street commentary on Surgery Partners centers on Q4 earnings that came in below expectations, margin pressure tied to anesthesia costs, and a less favorable payer mix.SGRY: Margin Reset And M&A Optionality Are Expected To Ease Payer Mix Pressures
The analyst fair value estimate for Surgery Partners has been reduced from $33.00 to $25.00 as analysts factor in lower Q4 EBITDA, margin pressure related to payer mix and anesthesia costs, and softer 2026 guidance that assumes fewer deals than previously modeled. Analyst Commentary Street research has broadly reset expectations on Surgery Partners, with several firms lowering their price targets after Q4 results and the updated 2026 outlook.
SGRY: New Baylor Partnership Will Set Up Future Multiple Rebound Potential
Analysts have kept their $18.00 price target for Surgery Partners unchanged, citing consistent assumptions regarding revenue growth, profit margins, and future P/E as support for this view. What's in the News Surgery Partners agreed to a new partnership with Baylor Scott & White Health to jointly own The Physicians Centre Hospital, a 16 bed facility in Bryan, Texas, alongside physicians (Key Developments).SGRY: Payer Mix Pressures Will Set Up Future Multiple Rebound Potential
Analysts have reduced their price target on Surgery Partners to US$18 from US$24, citing weaker earnings visibility from payer mix and volume pressures, a higher discount rate, more conservative revenue growth assumptions, and an adjustment to a lower future P/E multiple. Analyst Commentary Recent research updates on Surgery Partners point to a reset in expectations, with several firms cutting price targets across the board.SGRY: Asset Divestitures And Deleveraging Are Expected To Reset Payer Mix Pressures
Narrative Update Analysts have reduced their price targets on Surgery Partners to a range of roughly US$18 to US$31, citing lower earnings visibility tied to payer mix and volume pressures, slower M&A activity, and updated guidance that still assumes a favorable backdrop for asset divestitures and ambulatory surgery center demand. Analyst Commentary Across recent research updates, analysts have generally reduced price targets for Surgery Partners into the US$18 to US$31 range while still highlighting several areas that they see as supportive for the equity story.SGRY: Upcoming Divestitures And Deleveraging Will Support A Constructive 2025 Reset
Analysts have trimmed their price targets on Surgery Partners, resulting in a modest change in estimated fair value from about $25.73 to $25.45, as they factor in payer mix pressure, softer recent performance, slower M&A activity, and updated expectations for volumes and earnings visibility. Analyst Commentary Recent research paints a mixed picture for Surgery Partners, with price targets moving lower but opinions split on how temporary the current pressures might be.SGRY: Upcoming Asset Divestitures Are Expected To Drive Material Balance Sheet Deleveraging
Analysts have trimmed their fair value estimate for Surgery Partners to $33 from $36. This reflects lower price targets across the Street as they factor in softer volume trends, payer mix headwinds, reduced earnings visibility and a slower M&A cadence, partially offset by confidence in long term ASC tailwinds and de-leveraging from asset divestitures.SGRY: Upcoming Divestitures And Deleveraging Will Drive A Constructive Reset In 2025
Surgery Partners price target has been revised lower, with analysts trimming expectations by mid single digit dollars per share to reflect weaker than expected recent performance, payer mix and volume pressures, slower M&A activity, and reduced near term earnings visibility, even as they highlight supportive long term fundamentals and a still constructive outlook on asset divestitures and deleveraging. Analyst Commentary Analysts are broadly revising models to reflect weaker near term trends, yet most still frame the stock as a valuation reset rather than a change in the long term thesis.SGRY: Upcoming Divestitures And Deleveraging Will Drive Recovery In 2025
Analysts have lowered their price target for Surgery Partners from approximately $27.91 to $25.73. They cite recent earnings misses, payer mix headwinds, and delayed acquisitions as primary factors for the revision.SGRY: Asset Divestitures And Acquisition Pipeline Will Drive Recovery Ahead
The analyst price target for Surgery Partners has decreased from $31 to approximately $27.91. Analysts cite lowered guidance due to slowing volume and payer mix trends, a delay in acquisitions, and a more cautious outlook for near-term growth.Surgery Partners: Deleveraging Needs To Be The Priority
Sep 08Ambulatory Surgery Trends And Aging Will Expand Market Reach
Growth is driven by rising surgical case volumes in lower-cost centers and expanded specialties, supported by demographic trends and strategic network expansion.Surgery Partners: A Buyout Could Be Justifiable Around This Level
Jan 30Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues Pushing Shares 28% Lower
Dec 08
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt
Nov 11Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues
Oct 24Surgery Partners (NASDAQ:SGRY) Has Some Way To Go To Become A Multi-Bagger
Oct 05Surgery Partners, Inc. (NASDAQ:SGRY) Soars 25% But It's A Story Of Risk Vs Reward
Jul 25Here's Why Surgery Partners (NASDAQ:SGRY) Has A Meaningful Debt Burden
Jul 13Slowing Rates Of Return At Surgery Partners (NASDAQ:SGRY) Leave Little Room For Excitement
Jun 21We Think Shareholders Are Less Likely To Approve A Pay Rise For Surgery Partners, Inc.'s (NASDAQ:SGRY) CEO For Now
May 31Surgery Partners, Inc.'s (NASDAQ:SGRY) Share Price Matching Investor Opinion
Apr 24Surgery Partners' (NASDAQ:SGRY) Returns Have Hit A Wall
Mar 18Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt
Feb 27The Price Is Right For Surgery Partners, Inc. (NASDAQ:SGRY)
Dec 19Returns Are Gaining Momentum At Surgery Partners (NASDAQ:SGRY)
Oct 26Does Surgery Partners (NASDAQ:SGRY) Have A Healthy Balance Sheet?
Sep 17Are Investors Undervaluing Surgery Partners, Inc. (NASDAQ:SGRY) By 35%?
Aug 26The Return Trends At Surgery Partners (NASDAQ:SGRY) Look Promising
Jul 21Surgery Partners, Inc.'s (NASDAQ:SGRY) Shareholders Might Be Looking For Exit
Jun 15A Look At The Intrinsic Value Of Surgery Partners, Inc. (NASDAQ:SGRY)
May 26There's Been No Shortage Of Growth Recently For Surgery Partners' (NASDAQ:SGRY) Returns On Capital
Apr 14Rendement pour les actionnaires
| SGRY | US Healthcare | US Marché | |
|---|---|---|---|
| 7D | -0.5% | 3.5% | 0.8% |
| 1Y | -38.2% | -3.2% | 27.7% |
Rendement vs Industrie: SGRY a sous-performé le secteur US Healthcare qui a rapporté -2.3 % au cours de l'année écoulée.
Rendement vs marché: SGRY a sous-performé le marché US qui a rapporté 28.7 % au cours de l'année écoulée.
Volatilité des prix
| SGRY volatility | |
|---|---|
| SGRY Average Weekly Movement | 6.5% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Cours de l'action stable: SGRY n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de SGRY ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2004 | 16,000 | J. Evans | www.surgerypartners.com |
Surgery Partners, Inc. et ses filiales possèdent et gèrent un réseau d'établissements chirurgicaux et de services auxiliaires aux États-Unis. La société propose des centres de chirurgie ambulatoire et des hôpitaux chirurgicaux qui offrent des procédures chirurgicales non urgentes dans diverses spécialités, notamment l'orthopédie et la gestion de la douleur, l'ophtalmologie, la gastro-entérologie et la chirurgie générale. Il propose des services d'urgence, des services auxiliaires tels que des cabinets médicaux et des tests de diagnostic, des cabinets médicaux multi-spécialités, des centres de soins d'urgence et des services d'anesthésie.
Surgery Partners, Inc. Résumé des fondamentaux
| SGRY statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$1.82b |
| Bénéfices(TTM) | -US$77.90m |
| Recettes(TTM) | US$3.31b |
0.6x
Ratio P/S-23.7x
Ratio P/ELe site SGRY est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| SGRY compte de résultat (TTM) | |
|---|---|
| Recettes | US$3.31b |
| Coût des recettes | US$2.54b |
| Marge brute | US$765.00m |
| Autres dépenses | US$842.90m |
| Les revenus | -US$77.90m |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
May 05, 2026
| Résultat par action (EPS) | -0.60 |
| Marge brute | 23.12% |
| Marge bénéficiaire nette | -2.35% |
| Ratio dettes/capitaux propres | 78.8% |
Quelles ont été les performances à long terme de SGRY?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/01 00:34 |
| Cours de l'action en fin de journée | 2026/05/01 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Surgery Partners, Inc. est couverte par 23 analystes. 11 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Steven Valiquette | Barclays |
| Steven Valiquette | Barclays |
| Sarah James | Barclays |